Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Kidney
Descriptor: Mutation of Met


Reference Number: 64
Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 95, 14417-22 (1998).
PubMed link      E-mail link

Reference Number: 65
Lorenzato, A. et al. d invasion. Cancer Res 62, 7025-30 (2002).
PubMed link      E-mail link

Reference Number: 66
Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82, 640-3 (1999).
PubMed link      E-mail link

Reference Number: 67
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16, 68-73 (1997).
PubMed link      E-mail link

Reference Number: 68
Schmidt, L. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58, 1719-22 (1998).
PubMed link      E-mail link

Reference Number: 69
Schmidt, L. et al. . Oncogene 18, 2343-50. (1999).
PubMed link      E-mail link

Reference Number: 276
Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18:5221-31 (1999).
PubMed link      E-mail link

Reference Number: 277
Maritano D, Accornero P, Bonifaci N, Ponzetto C. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene 19:1354-61 (2000).
PubMed link      E-mail link

Reference Number: 278
Chiara F, Michieli P, Pugliese L, Comoglio PM. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. J Biol Chem. 278, 29352-8 (2003)
PubMed link      E-mail link

Reference Number: 279

Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 44, 32-43 (2001)

PubMed link      E-mail link

Reference Number: 280
Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, Warren MB, Choyke PL, Torres-Cabala CA, Merino MJ, Brunet J, Berez V, Borras J, Sesia G, Middelton L, Phillips JL, Stolle C, Zbar B, Pautler SE, Linehan WM. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172, 1256-61 (2004)
PubMed link      E-mail link

Reference Number: 330
Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101, 17198-203 (2004)


PubMed link      E-mail link

Reference Number: 335
Prat E, Bernués M, Del Rey J, Camps J, Ponsa I, Algaba F, Egozcue J, Caballín MR, Gelabert A, Miró R. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma. Cancer Genet Cytogenet. 164, 142-7 (2006)
PubMed link      E-mail link

Reference Number: 340
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 5387-93 (2004)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 638
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 33, 271-6 (2008)
PubMed link      E-mail link

Reference Number: 686
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 44, 641-51. (2008) Epub 2008 Mar 4

PubMed link      E-mail link

Reference Number: 726
Resorlu B, Baltaci S, Resorlu M, Kankaya D, Savas B. Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. Turk J Gastroenterol. 18, 47-9 (2007)
PubMed link      E-mail link

Reference Number: 929
Lim JC, Wojcik EM. Fine-needle aspiration cytology of papillary renal cell carcinoma: the association with concomitant secondary malignancies. Diagn Cytopathol. 34, 797-800 (2006)
PubMed link      E-mail link

Reference Number: 981
Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 94, 11445-50 (1997)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1023
Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test. 5, 101-6 (2001)
PubMed link      E-mail link

Reference Number: 1262
Wadt KA, Gerdes AM, Hansen TV, Toft BG, Friis-Hansen L, Andersen MK. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. Fam Cancer. 11, 535-7 (2012)
PubMed link      E-mail link

Reference Number: 1378
Harshman LC1, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 19, 316-23 (2013)
PubMed link      E-mail link

Reference Number: 1547
Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 21, 81-90 (2014)
PubMed link      E-mail link

Reference Number: 1604
Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allory Y, Orear C, Couvé S, Gad S, Patard JJ, Escudier B. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 20, 3411-21 (2014)
PubMed link      E-mail link

Reference Number: 1643
Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 47, 13-21 (2015)
PubMed link      E-mail link

Reference Number: 1868
Garcia-Donas J, Rodriguez-Moreno JF, Romero-Laorden N, Rodriguez-Antona C. Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urol Oncol. 33, 179-86 (2015)
PubMed link      E-mail link